🧠 This Week in Neuroscience: MS Guidelines, ALS Gene Therapy, Dementia Risks, Intranasal Breakthroughs and More
Explore the latest wave of innovation in neuroscience! This week’s update dives into national MS treatment shifts, fast-tracked CNS delivery technologies, cutting-edge RNA partnerships, and a bold leap in ALS gene therapy. From stem cell-driven remyelination to the growing conversation around gabapentin and dementia risk—this roundup brings you closer to the future of brain science.
📌 What’s Inside This Week’s Update
🇷🇺 Russia updates its MS guidelines, now officially including domestic therapies from Biocad and Valenta Pharm
🇰🇷 Korea nears approval of a 10-minute subcutaneous Ocrevus injection—dramatically reducing treatment time
🚀 Quantum BioPharma fast-tracks its novel MS candidate, Lucid-MS, through the UK’s ILAP pathway
🧠 A new study links gabapentin to a twenty-nine percent higher dementia risk and eighty-five percent increased MCI risk
🤝 Secarna and Vect-Horus partner to cross the blood-brain barrier with RNA-based CNS therapies
👃 MetP® tech enables semaglutide brain delivery via the nose—surpassing both oral and SC routes
💸 Illimis raises $42M to fuel its CNS and immune programs, with strong ties to Eli Lilly and J&J
🧬 Stem cell grafts restore myelin in MS mouse models—human trials show promising safety
🇨🇳 Zhimeng’s ALS drug secures approval for Phase 2/3 in China, targeting potassium channels
🧍♂️ Neumora launches human trials for NMRA-861, a novel schizophrenia M4 modulator
🧒 Rugonersen shows early brain function gains in children with Angelman syndrome
🧬 KLTO-202 granted FDA Orphan Drug Designation for ALS gene therapy using secreted Klotho
📉 Capricor’s DMD therapy denied FDA approval—plans resubmission after HOPE-3 data
💊 J&J files CAPLYTA for relapse prevention in schizophrenia—Phase 3 shows sixty-three percent risk reduction
From fast-acting MS injections to emerging gene therapies, this week highlights how neuroscience is redefining patient care and therapeutic possibility.
📢 Stay Ahead in Neuroscience Research!
✅ Like, share, and subscribe for weekly updates on neuroscience and neurodegenerative breakthroughs
🌐 Visit www.lqventures.com for expert healthcare insights and consulting services
📩 Contact LucidQuest at info@lqventures.com for strategic guidance on neuroscience innovations and clinical research
🔔 Turn on notifications so you never miss an update!
#Neuroscience #MultipleSclerosis #ALS #GeneTherapy #CNSdelivery #BrainHealth #ClinicalResearch #NeurologyNews #RNAtherapeutics #BiotechInnovation #LucidQuest #StemCellTherapy #DementiaRisk #HealthcareConsulting #NeuroscienceUpdates #FDAnews